2. Search Result
Search Result
Results for "

sedation

" in MedChemExpress (MCE) Product Catalog:

36

Inhibitors & Agonists

5

Natural
Products

4

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-119456
    Romifidine

    		Adrenergic Receptor Neurological Disease
    Romifidine is an α2 adrenergic receptor agonist. Romifidine shows sedation effects in vivo .
    Romifidine
  • HY-B0649
    Propofol
    10+ Cited Publications

    2,6-Diisopropylphenol

    		 GABA Receptor Endogenous Metabolite Neurological Disease Cancer
    Propofol potently and directly activates GABAA receptor and inhibits glutamate receptor mediated excitatory synaptic transmission. Propofol has antinociceptive properties and is used for sedation and hypnotic .
    Propofol
  • HY-17034A
    Dexmedetomidine hydrochloride
    Maximum Cited Publications
    12 Publications Verification

    (+)-Medetomidine hydrochloride; (S)-Medetomidine hydrochloride

    		 Adrenergic Receptor Neurological Disease Endocrinology Cancer
    Dexmedetomidine hydrochloride ((+)-Medetomidine hydrochloride) is a potent, selective and orally active agonist of α2-adrenoceptor, with a Ki of 1.08 nM. Dexmedetomidine hydrochloride shows 1620-fold selectivity against α1-adrenoceptor. Dexmedetomidine hydrochloride exhibits anxiolysis, sedation, and modest analgesia effects .
    Dexmedetomidine hydrochloride
  • HY-12719
    Dexmedetomidine
    Maximum Cited Publications
    12 Publications Verification

    (+)-Medetomidine; (S)-Medetomidine

    		 Adrenergic Receptor Neurological Disease Cancer
    Dexmedetomidine ((+)-Medetomidine) is a potent, selective and orally active agonist of α2-adrenoceptor, with a Ki of 1.08 nM. Dexmedetomidine shows 1620-fold selectivity against α1-adrenoceptor. Dexmedetomidine exhibits anxiolysis, sedation, and modest analgesia effects .
    Dexmedetomidine
  • HY-13575
    Blonanserin
    1 Publications Verification

    AD-5423

    		 5-HT Receptor Dopamine Receptor Adrenergic Receptor Sigma Receptor Cardiovascular Disease Neurological Disease
    Blonanserin (AD-5423) is a potent?and orally active 5-HT2A?(Ki=0.812 nM) and?dopamine D2?receptor?(Ki =0.142?nM)?antagonist. Blonanserin is usually acts as an atypical antipsychotic?agent and can be used for the research of extrapyramidal symptoms, excessive?sedation, or?hypotension .
    Blonanserin
  • HY-119456A
    Romifidine hydrochloride

    		Adrenergic Receptor Neurological Disease
    Romifidine hydrochloride is an α2 adrenergic receptor agonist. Romifidine hydrochloride shows sedation effects in vivo .
    Romifidine hydrochloride
  • HY-W749797
    Nitrazolam

    		GABA Receptor Neurological Disease
    Nitrazolam is a benzodiazepine compound, that may exhibit CNS depressant properties as traditional benzodiazepines, including sedation, hypnosis, anxiolysis, and anticonvulsant effects, by acting on GABA receptors .
    Nitrazolam
  • HY-12719R
    Dexmedetomidine (Standard)

    		Adrenergic Receptor Neurological Disease Cancer
    Dexmedetomidine (Standard) is the analytical standard of Dexmedetomidine. This product is intended for research and analytical applications. Dexmedetomidine ((+)-Medetomidine) is a potent, selective and orally active agonist of α2-adrenoceptor, with a Ki of 1.08 nM. Dexmedetomidine shows 1620-fold selectivity against α1-adrenoceptor. Dexmedetomidine exhibits anxiolysis, sedation, and modest analgesia effects .
    Dexmedetomidine (Standard)
  • HY-19057
    Vatinoxan

    MK-467; L-659066

    		 Adrenergic Receptor Cardiovascular Disease Neurological Disease
    Vatinoxan (MK-467) is an alpha 2-adrenergic receptor antagonist. The peripheral selectivity of Vatinoxan determines that it has limited penetration across the blood-brain barrier and therefore has low concentrations in the central nervous system. Vatinoxan antagonizes alpha 2-adrenergic receptor receptors by binding to them, thereby reducing or preventing cardiovascular effects caused by α2-adrenergic agonists. Vatinoxan can be used in studies of cardiovascular effects, sedation and analgesia .
    Vatinoxan
  • HY-13575R
    Blonanserin (Standard)

    		5-HT Receptor Dopamine Receptor Adrenergic Receptor Sigma Receptor Neurological Disease
    Blonanserin (Standard) is the analytical standard of Blonanserin. This product is intended for research and analytical applications. Blonanserin (AD-5423) is a potent and orally active 5-HT2A (Ki=0.812 nM) and dopamine D2 receptor (Ki =0.142 nM) antagonist. Blonanserin is usually acts as an atypical antipsychotic agent and can be used for the research of extrapyramidal symptoms, excessive sedation, or hypotension .
    Blonanserin (Standard)
  • HY-103496
    U-90042

    		GABA Receptor Others
    U-90042 is a gamma-aminobutyric acidA receptor agonist of α1, α3 and α6 subtypes with Ki values of 7.8 nM, 9.5 nM and 11.0 nM, respectively. U-90042 suppresses locomotor activity and impairs rotarod performance in mice. U-90042 produces sedation and ataxia and prolongs sleeping time in mice, rats and monkeys. U-90042 can be used as a sedative and hypnotic agent .
    U-90042
  • HY-17416
    Guanfacine hydrochloride
    2 Publications Verification

    		 Adrenergic Receptor Cardiovascular Disease Endocrinology
    Guanfacine hydrochloride is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD) .
    Guanfacine hydrochloride
  • HY-17416A
    Guanfacine
    2 Publications Verification

    		 Adrenergic Receptor Cardiovascular Disease Neurological Disease Endocrinology
    Guanfacine is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD) .
    Guanfacine
  • HY-17416S2
    Guanfacine-13C,d5 hydrochloride

    		Adrenergic Receptor Isotope-Labeled Compounds Cardiovascular Disease Endocrinology
    Guanfacine- 13C,d5 hydrochloride is the deuterium and 13C labeled Guanfacine hydrochloride (HY-17416). Guanfacine hydrochloride is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD) .
    Guanfacine-13C,d5 hydrochloride
  • HY-17416R
    Guanfacine (hydrochloride) (Standard)

    		Adrenergic Receptor Cardiovascular Disease Endocrinology
    Guanfacine (hydrochloride) (Standard) is the analytical standard of Guanfacine (hydrochloride). This product is intended for research and analytical applications. Guanfacine hydrochloride is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD) .
    Guanfacine (hydrochloride) (Standard)
  • HY-17416AS1
    Guanfacine-15N3,13C2

    		Adrenergic Receptor Isotope-Labeled Compounds Neurological Disease Endocrinology
    Guanfacine- 15N3, 13C2 is 15N and 13C labeled Guanfacine (HY-17416A). Guanfacine is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD) .
    Guanfacine-15N3,13C2
  • HY-16505
    Triclofos sodium

    		Endogenous Metabolite Neurological Disease
    Triclofos sodium is a drug used to suppress insomnia and for sedation and has sedative activity. Triclofos sodium is used in children for sedation during painless medical procedures, particularly in children with neurocognitive disorders. Triclofos sodium has similar physiological and pharmacological properties to chloral and therefore can be used as a substitute when necessary. The safety and efficacy of Triclofos sodium have been demonstrated in pediatric populations with high rates of neurocognitive disorders .
    Triclofos sodium
  • HY-117257
    PF-0713

    		GABA Receptor Cancer
    PF 0713 is a GABAA receptor agonist. .
    PF-0713
  • HY-19006
    ZK-91296

    		GABA Receptor Neurological Disease
    ZK-91296 is a GABA receptor agonist with anxiolytic activity. ZK-91296 can reduce anxiety in animals without causing sedation. ZK-91296 may have pharmacological selectivity for interaction with specific types of benzodiazepine receptors .
    ZK-91296
  • HY-B0649R
    Propofol (Standard)

    2,6-Diisopropylphenol (Standard)

    		 GABA Receptor Endogenous Metabolite Neurological Disease Cancer
    Propofol (Standard) is the analytical standard of Propofol. This product is intended for research and analytical applications. Propofol potently and directly activates GABAA receptor and inhibits glutamate receptor mediated excitatory synaptic transmission. Propofol has antinociceptive properties and is used for sedation and hypnotic .
    Propofol (Standard)
  • HY-113346
    Tetrahydrodeoxycorticosterone

    Tetrahydro-11-deoxycorticosterone

    		 GABA Receptor Endogenous Metabolite Neurological Disease
    Tetrahydrodeoxycorticosterone, an neurosteroid, is a potent positive allosteric modulator (PAM) of GABAA receptor. Tetrahydrodeoxycorticosterone has potent neuroinhibitory properties .
    Tetrahydrodeoxycorticosterone
  • HY-B1240
    Droperidol
    3 Publications Verification

    Dehydrobenzperidol

    		 Dopamine Receptor GABA Receptor nAChR Neurological Disease
    Droperidol (Dehydrobenzperidol) is a butyrophenone pamine-2 receptor antagonist that inhibits the activation of GABA(A) and neuronal nicotinic receptors (nAChR), with IC50 values of 12.6 nM and 5.8 μM. Droperidol has anesthetic and sedative properties .
    Droperidol
  • HY-13575A
    Blonanserin dihydrochloride

    AD-5423 dihydrochloride

    		 5-HT Receptor Dopamine Receptor Adrenergic Receptor Sigma Receptor Cardiovascular Disease Neurological Disease
    Blonanserin dihydrochloride is a potent and orally active 5-HT2A and dopamine D2 receptor antagonist, with Ki values of 0.812 and 0.142 nM, respectively. Blonanserin dihydrochloride is usually acts as an atypical antipsychotic agent, and can be used for the research of extrapyramidal symptoms, excessive sedation, or hypotension .
    Blonanserin dihydrochloride
  • HY-N0528
    Linarin

    Buddleoside; Linarine

    		 TNF Receptor Cholinesterase (ChE) PKA Apoptosis Bacterial HIV Influenza Virus Infection Neurological Disease Inflammation/Immunology Cancer
    Linarin (Buddleoside) is an orally active and selective inhibitor of acetylcholinesterase (AChE). Linarin has many activities, such as anti-inflammatory, antioxidant, sleep aid and sedation, bone differentiation, anti-tumor, antibacterial and antiviral. Linarin can be used to study diseases such as the nervous system, osteoporosis and cancer .
    Linarin
  • HY-B1196A
    Tiapride

    		Dopamine Receptor Neurological Disease
    Tiapride, an atypical neuroleptic agent, is a selective dopamine D2-receptor antagonist with little propensity for causing catalepsy and sedation. The IC50 values of Tiapride are 1440, 45.8, >100, and 11.7 μM for D1; D2; D3; D4, respectively .
    Tiapride
  • HY-148146
    Phenoxypropazine

    		Monoamine Oxidase Neurological Disease
    Phenoxypropazine is a potent monoamine oxidase (MAO) inhibitor. Phenoxypropazine can be used in research of depression .
    Phenoxypropazine
  • HY-N0528R
    Linarin (Standard)

    		TNF Receptor Cholinesterase (ChE) PKA Apoptosis Bacterial HIV Influenza Virus Infection Neurological Disease Inflammation/Immunology Cancer
    Linarin (Standard) is the analytical standard of Linarin. This product is intended for research and analytical applications. Linarin (Buddleoside) is an orally active and selective inhibitor of acetylcholinesterase (AChE). Linarin has many activities, such as anti-inflammatory, antioxidant, sleep aid and sedation, bone differentiation, anti-tumor, antibacterial and antiviral. Linarin can be used to study diseases such as the nervous system, osteoporosis and cancer.
    Linarin (Standard)
  • HY-167865
    O-1269

    		Cannabinoid Receptor Neurological Disease
    O-1269 is a partial agonist of cannabinoid receptor 1 (CB1R) with a Ki of 32 nM. O-1269 shows analgesic effects .
    O-1269
  • HY-12752A
    Alimemazine hemitartrate

    Trimeprazine hemitartrate

    		 Histamine Receptor Influenza Virus Neurological Disease Inflammation/Immunology Cancer
    Alimemazine hemitartrate (Trimeprazine hemitartrate) is an antagonist of the histamine (HA) receptor that can be taken orally and also acts as a partial agonist at other GPCR receptors. Alimemazine hemitartrate has effects that include anti-serotonin, antispasmodic, antihistamine, sedation, hypnotic, antiviral, and anti-nausea properties. Alimemazine hemitartrate promotes the growth of pancreatic β-cells in mice and improves diabetes in mice .
    Alimemazine hemitartrate
  • HY-17034AR
    Dexmedetomidine (hydrochloride) (Standard)

    (+)-Medetomidine (hydrochloride) (Standard); (S)-Medetomidine (hydrochloride) (Standard)

    		 Adrenergic Receptor Neurological Disease Endocrinology Cancer
    Dexmedetomidine (hydrochloride) (Standard) is the analytical standard of Dexmedetomidine (hydrochloride). This product is intended for research and analytical applications. Dexmedetomidine hydrochloride ((+)-Medetomidine hydrochloride) is a potent, selective and orally active agonist of α2-adrenoceptor, with a Ki of 1.08 nM. Dexmedetomidine hydrochloride shows 1620-fold selectivity against α1-adrenoceptor. Dexmedetomidine hydrochloride exhibits anxiolysis, sedation, and modest analgesia effects .
    Dexmedetomidine (hydrochloride) (Standard)
  • HY-17034AS
    Dexmedetomidine-13C,d3 hydrochloride

    (+)-Medetomidine-13C,d3 hydrochloride; (S)-Medetomidine-13C,d3 hydrochloride

    		 Isotope-Labeled Compounds Adrenergic Receptor Neurological Disease Endocrinology Cancer
    Dexmedetomidine- 13C,d3 (hydrochloride) is the 13C- and deuterium labeled Dexmedetomidine (hydrochloride). Dexmedetomidine hydrochloride ((+)-Medetomidine hydrochloride) is a potent, selective and orally active agonist of α2-adrenoceptor, with a Ki of 1.08 nM. Dexmedetomidine hydrochloride shows 1620-fold selectivity against α1-adrenoceptor. Dexmedetomidine hydrochloride exhibits anxiolysis, sedation, and modest analgesia effects[1][2][3].
    Dexmedetomidine-13C,d3 hydrochloride
  • HY-125047
    Daledalin tosylate

    UK 3557

    		 Monoamine Oxidase Neurological Disease
    Daledalin tosylate (UK 3557) has mono-amine oxidase inhibitory activity in vitro, probably by acting as a substrate. Daledalin tosylate also has antidepressant effects. Daledalin tosylate potentiates amphetamine-induced excitation in rats, antagonises Reserpine (HY-N0480)-hypothermia in mice, tetrabenazine-sedation in rats and Reserpine (HY-N0480)- and Tetrabenazine (HY-B0590)-induced ptosis in mice with . Daledalin tosylate is proming for rasearch of depressive illness .
    Daledalin tosylate
  • HY-17416AS
    Guanfacine-13C,15N3

    		Adrenergic Receptor Neurological Disease
    Guanfacine- 13C, 15N3 is the 13C and 15N labeled Guanfacine[1]. Guanfacine is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD)[2][3][4].
    Guanfacine-13C,15N3
  • HY-123525
    COR628

    		GABA Receptor Neurological Disease
    COR628 is a positive allosteric modulator of GABA(B) receptors with the activity of enhancing GABA-induced GTPγS stimulation. COR628 showed significant activity in in vitro studies but did not exhibit endogenous agonist activity. COR628 has shown efficacy in experiments in mice by enhancing the sedation/hypnosis induced by baclofen, shortening the onset time and extending the duration of loss of righting reflex when combined with non-sedating doses of baclofen . The cytotoxic effect of COR628 is comparable to or higher than that of GS39783 or BHF177 in concentration .
    COR628
  • HY-159924
    DBPR116

    		Opioid Receptor Neurological Disease
    DBPR116 is a prodrug of BPRMU191 (HY-159923) with blood-brain barrier penetration capability. DBPR116 significantly improves the delivery of centrally targeted drugs. In combination with the antagonist Naltrexone (HY-76711), DBPR116 demonstrated superior safety and analgesic efficacy compared to morphine in various in vivo pharmacological studies, including thermal pain models, cancer pain models, constipation, sedation, psychological dependence, heart rate, and respiratory frequency. As a prodrug strategy for peripheral administration, DBPR116 effectively alleviates pain while reducing adverse effects, showing potential as a safer opioid analgesic .
    DBPR116
  • HY-111136
    BL-1020 mesylate

    		GABA Receptor 5-HT Receptor Dopamine Receptor Histamine Receptor Neurological Disease
    BL-1020 mesylate is the mesylate salt form of BL-1020. BL-1020 mesylate is an antipsychotic agent. BL-1020 mesylate is inhibitor for dopamine receptor and serotonin receptor (5-HT receptor), with Ki of 0.066, 0.062 and 0.21 nM, for D2L, D2S and 5-HT2A receptors, respectively. BL-1020 mesylate is agonist for GABAA receptor with Ki of 3.74 μM, and enhances the GABA release. BL-1020 mesylate exhibits high affinity with histamine receptor (Ki is 0.47 nM). BL-1020 mesylate reduces Amphetamine-induced hyperactivity, with lower catalepsy and sedation. BL-1020 mesylate is blood-brain barrier penetrate .
    BL-1020 mesylate

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: